## 503539735 10/26/2015

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT3586362

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

#### **CONVEYING PARTY DATA**

Name	Execution Date
SAMUEL J. DANISHEFSKY	10/08/2015
JENNIFER R. ALLEN	10/09/2015
GOVINDASWAMI RAGUPATHI	10/06/2015
PHILIP O. LIVINGSTON	10/05/2015
LAWRENCE WILLIAMS	10/08/2015

#### **RECEIVING PARTY DATA**

Name:	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
Street Address:	1275 YORK AVENUE
City:	NEW YORK
State/Country:	NEW YORK
Postal Code:	10065

### **PROPERTY NUMBERS Total: 1**

Property Type	Number
Application Number:	14148500

#### **CORRESPONDENCE DATA**

**Fax Number:** (617)502-4095

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

**Phone:** 617-248-5000

**Email:** patentdocket@choate.com

Correspondent Name: CHOATE, HALL & STEWART, LLP
Address Line 1: TWO INTERNATIONAL PLACE
Address Line 4: BOSTON, MASSACHUSETTS 02110

ATTORNEY DOCKET NUMBER: 2003080-0629

NAME OF SUBMITTER: XIAODONG LI, PHD

SIGNATURE: /Xiaodong Li/


DATE SIGNED: 10/26/2015

This document serves as an Oath/Declaration (37 CFR 1.63).

**Total Attachments: 9** 

PATENT REEL: 036881 FRAME: 0563

503539735



PATENT REEL: 036881 FRAME: 0564

Docket Number: 2003080-0629

#### COMBINED JOINT ASSIGNMENT & DECLARATION

### A. ASSIGNMENT

WHEREAS, each of the below-named inventors whose name and residence is set forth in the following Table 1:

Inventor Name	City, State
1. Samuel J. Danishefsky	Englewood, New Jersey
2. Jennifer R. Allen	Indianapolis, Indiana
3. Govindaswami Ragupathi	New York, New York
4. Philip O. Livingston	New York, New York
5. Lawrence Williams	New York, New York

Table 1

hereby declares and agrees, on behalf of himself/herself and all of his/her successors and assigns that each is aware of the patent application(s) entitled:

# NOVEL GLYCOCONJUGATES, GLYCOAMINO ACIDS, INTERMEDIATES THERETO, AND USES THEREOF; and

prepar	red for filing in the United St	ates Patent and	Гrademark Office; or	
x identif	ied by United States Applica	tion Serial No.	14/148,500	
filed in the Unite	d States Patent and Trademar	k Office on;	January 6, 2014	; and
filed on	also aware of the following	; and	ions:	
	Serial No.		Filed	
	13/018,249	Janu	ary 31, 2011	
	09/641,742	Aug	gust 18, 2000	
	60/150,088	Aug	gust 20, 1999	

WHEREAS Sloan-Kettering Institute for Cancer Research (hereinafter "ASSIGNEE"), having a usual place of business at 1275 York Avenue, New York, New York 10065, desires to acquire or confirm an interest therein;

Page 1 of 9

NOW, THEREFORE, to all whom it may concern be it known that, in consideration of agreements previously and duly entered into between the parties, and/or for other good and valuable consideration, the receipt of which is hereby acknowledged, each of us has sold, assigned, and transferred and/or do hereby sell, assign, and transfer unto said ASSIGNEE, its successors, assigns, and legal representatives, my entire right, title, and interest in and throughout the United States of America, its territories and all foreign countries, in and to any and all inventions described in the patent application, and/or any priority applications noted above, including any right of priority thereto; and hereby confirm that my sale, assignment and transfer is and was effective at least as of the filing date of the patent application and/or priority application. Our sale, assignment and transfer applies to the above-referenced patent application, and to any application that is based in whole or in part on the patent application, including any divisional, continuing, substitute, renewal, reissue, reexamination and other applications, for example that claim priority to the patent application. Also, this sale, assignment and transfer pertains to any and all other rights arising under or pursuant to any and all international agreements, treaties, or laws relating to the protection of industrial property, including all rights of priority under the International Convention for the Protection of Industrial Property, and in and to any such patent(s) as may issue thereon including any and all original and reissued patents which have been or shall be issued in the United States and foreign countries; said inventions, applications, and patent(s) to be held and enjoyed by ASSIGNEE for its own use and for its successors, assigns and legal representatives, to the full end of the term for which said patent(s) may be granted as fully and entirely as the same would have been held by each of us had this sale, assignment and transfer not been made;

AND, each of us hereby acknowledges that this Assignment, being of our entire right, title, and interest in and to the inventions, carries with it the right in ASSIGNEE, by attorneys and agents of ASSIGNEE selection, to apply for and receive any and all patent(s) for said inventions in its own name;

AND, each of us hereby further agrees for ourselves and our executors and administrators to execute upon request any other lawful documents and likewise to perform any other lawful acts which may be deemed necessary to secure fully the patent(s) to ASSIGNEE, its successors, assignees, and legal representatives, but at its expense and charges, including the execution of application for patents in foreign countries, the execution of substitution, reissue, divisional or continuation applications, and the giving of testimony, preliminary statements, or other statements in any interference or other proceeding in which the inventions or any applications or patents directed to the inventions may be involved by communicating to the ASSIGNEE all facts we know relating to the inventions and their history, and generally by doing everything possible which ASSIGNEE shall consider desirable for aiding in securing and maintaining proper patent protection for the inventions and for vesting title in the inventions and all applications for patent and all patents on the inventions in ASSIGNEE;

AND, each of us further hereby authorizes ASSIGNEE or its attorneys or agents to insert the correct serial number(s) and/or filing date(s) into this assignment document, if appropriate;

AND, each of us hereby appoints ASSIGNEE as our common agent for purposes of prosecuting international patent applications and any national patent applications for which such common agency is recognized;

Page 2 of 9

AND, each of us hereby requests the Commissioner for Patents of the United States Patent and Trademark Office to issue any and all patent(s) as shall be granted upon said application or applications based thereon to ASSIGNEE, its successors, assigns, and legal representatives;

AND, each of us covenants with said ASSIGNEE that no assignment, grant, mortgage, license, or other agreement affecting the rights and property herein conveyed has been made to others by us, and that full right to convey the same as herein expressed is possessed by us.

Page 3 of 9

# B. DECLARATION (37 CFR 1.63)

As below named inventors, we hereby declare that:

This declaration is directed to the patent application entitled:

# NOVEL GLYCOCONJUGATES, GLYCOAMINO ACIDS, INTERMEDIATES THERETO, AND USES THEREOF; and

attached hereto or prepared for filing in the United Office; or	States Patent and Trademark
x identified by United States Application Serial No.	14/148,500
filed in the United States Patent and Trademark Office on	January 6, 2014 ; or
identified by International Patent Application No. filed on	
The above-identified application was made or authorized	d to be made by us.
We believe that we are the original joint inventors application.	of a claimed invention in the

We have reviewed and understand the contents of the application, including the claims

punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or

We hereby acknowledge that any willful false statement made in this declaration is

we have reviewed and understand the contents of the application, including the claims and are aware of the duty to disclose to the United States Patent and Trademark Office all information known to be material to patentability as defined in 37 CFR 1.56.

Page 4 of 9

Jan Dan 6	Oct. 8 2015
Name: Samuel J. Danishefsky	Date
Witness Signature:  Signature:  Name (please print): Signature Valle(5)	
Witness Signature:	
Agan Camana	10/4/15
Name (please print): Lourza (11/1/201)	

1 RAL	10-9-15
Name: Jennifer R. Allen	Date
Witness Signature: Esse Hu Flavington	
Essa Ha Harrington	10-9-15
Name (prease print).	Date
Witness Signature: Sender	
Sean Brown	10-9-15
Name (please print):	Date

Colupat	10/6/2015
Name: Govindaswami Ragupathi	Date
Witness Signature:	
Name (please print):	<u> </u>
Undantru M. Herre Witness Signature:	
Constantine M. Ceage	10/6/2015
Name (please print):	Date

Name: Philip O. Liyingston	10/5/2015 Date
Witness Signature:  Chr. Ab.  Chr. Ab.  Name (please print):	
Witness Signature:  Lucy Pan H mid  Name (please print): Lucy MANN mid	

Ranklik.	10.8.15
Name: Lawrence Williams	Date
Witness Signature: MAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	
70	1. 1
Minette 2 Steinbers	10/8/15
Name (please print):	Date '
Witness Signature: MUSUNGS	
Jill Mesonas	10/8/15
Name (please print):	Date /

2003080-0829

**RECORDED: 10/26/2015**